DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

Information source: University of Iowa
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: memantine (Drug); Placebo (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: University of Iowa

Official(s) and/or principal investigator(s):
Jerry L Lewis, MD, Principal Investigator, Affiliation: University of Iowa Hospitals and Clinic

Overall contact:
Jerry L. Lewis, MD, Phone: 319-384 5630, Email: jerry-lewis@uiowa.edu


The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

Clinical Details

Official title: Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.

Secondary outcome: Whether memantine will improve response of Depression to Electroconvulsive therapy.

Detailed description: Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Meets criteria for Major Depressive disorder

Exclusion Criteria:

- Neurological disease

- Mental retardation

- Seizure disorder

Locations and Contacts

Jerry L. Lewis, MD, Phone: 319-384 5630, Email: jerry-lewis@uiowa.edu

University of Iowa hosptitals and clinic, Iowa City, Iowa 50208, United States; Not yet recruiting
Jerry L Lewis, MD, Phone: 319-384-5630, Email: jerry-lewis@uiowa.edu
Laurie M McCormick, MD, Phone: 319-384-7136, Email: laruie-mccormick@uiowa.edu
Jerry L Lewus, MD, Principal Investigator
Additional Information

Starting date: November 2009
Last updated: October 1, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017